These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34386602)

  • 1. Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy.
    Lin HH; Hsu SJ; Lu SN; Chuang WL; Hsu CW; Chien RN; Yang SS; Su WW; Wu JC; Lee TH; Peng CY; Tseng KC; Qin A; Huang YW; Chen PJ
    JGH Open; 2021 Aug; 5(8):929-940. PubMed ID: 34386602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C.
    Hsu SJ; Yu ML; Su CW; Peng CY; Chien RN; Lin HH; Lo GH; Su WW; Kuo HT; Hsu CW; Yang SS; Yang SS; Tseng KC; Qin A; Huang YW; Chuang WL
    J Formos Med Assoc; 2021 Mar; 120(3):956-964. PubMed ID: 33077341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B.
    Huang YW; Hsu CW; Lu SN; Yu ML; Su CW; Su WW; Chien RN; Hsu CS; Hsu SJ; Lai HC; Qin A; Tseng KC; Chen PJ
    Hepatol Int; 2020 Dec; 14(6):997-1008. PubMed ID: 33099752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C.
    Chen CY; Chuang WL; Qin A; Zhang WH; Zhu LY; Zhang GQ; Chen JJ; Lo CC; Zhou X; Mao X; Shang J; Kuo HT; Xie W; Chen CH; Lo GH; Jun DW; Dang S; Tsai CY; Wang TF; Lai HH; Tseng KC; Huang YW; Chen PJ
    JGH Open; 2022 Nov; 6(11):782-791. PubMed ID: 36406648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment.
    Lo CC; Chuang WL; Kuo HT; Chen WM; Qin A; Tsai CY; Huang YW; Chen CY
    J Formos Med Assoc; 2024 Jan; 123(1):55-61. PubMed ID: 37666718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial.
    Huang YW; Qin A; Fang J; Wang TF; Tsai CW; Lin KC; Teng CL; Larouche R
    Br J Clin Pharmacol; 2022 May; 88(5):2396-2407. PubMed ID: 34907578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects.
    Huang YW; Tsai CY; Tsai CW; Wang W; Zhang J; Qin A; Teng C; Song B; Wang MX
    Adv Ther; 2021 Sep; 38(9):4756-4770. PubMed ID: 34328630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration.
    Miyachi N; Zagrijtschuk O; Kang L; Yonezu K; Qin A
    Clin Drug Investig; 2021 Apr; 41(4):391-404. PubMed ID: 33725322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
    Gisslinger H; Klade C; Georgiev P; Krochmalczyk D; Gercheva-Kyuchukova L; Egyed M; Rossiev V; Dulicek P; Illes A; Pylypenko H; Sivcheva L; Mayer J; Yablokova V; Krejcy K; Grohmann-Izay B; Hasselbalch HC; Kralovics R; Kiladjian JJ;
    Lancet Haematol; 2020 Mar; 7(3):e196-e208. PubMed ID: 32014125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities.
    Liu WD; Hou HA; Li KJ; Qin A; Tsai CY; Sheng WH
    Adv Ther; 2024 Feb; 41(2):847-856. PubMed ID: 38010606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection.
    Lurie Y; Rouzier-Panis R; Webster GJ; Dusheiko GM; Laughlin M; Jackson ML; Oren R
    Clin Gastroenterol Hepatol; 2005 Jun; 3(6):610-5. PubMed ID: 15952104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.
    Edahiro Y; Ohishi K; Gotoh A; Takenaka K; Shibayama H; Shimizu T; Usuki K; Shimoda K; Ito M; VanWart SA; Zagrijtschuk O; Qin A; Kawase H; Miyachi N; Sato T; Komatsu N; Kirito K
    Int J Hematol; 2022 Aug; 116(2):215-227. PubMed ID: 35430707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
    McHutchison J; Sulkowski M
    J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis.
    Huang YW; Qin A; Tsai CY; Chen PJ
    Viruses; 2022 May; 14(6):. PubMed ID: 35746606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.
    Qin A; Wu D; Li Y; Zhang J; Wang W; Shen W; Liao J; Lin S; Chang C; Chen H; Cui J; Su X
    Br J Clin Pharmacol; 2024 Jun; 90(6):1493-1502. PubMed ID: 38500445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated interferons for the treatment of chronic hepatitis C infection.
    Luxon BA; Grace M; Brassard D; Bordens R
    Clin Ther; 2002 Sep; 24(9):1363-83. PubMed ID: 12380630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
    Jin J; Qin A; Zhang L; Shen W; Wang W; Zhang J; Li Y; Wu D; Xiao Z
    Future Oncol; 2023 Apr; 19(11):753-761. PubMed ID: 37129584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population.
    Jin YJ; Lee JW; Lee JI; Park SH; Park CK; Kim YS; Jeong SH; Kim YS; Kim JH; Hwang SG; Rim KS; Yim HJ; Cheong JY; Cho SW; Lee JS; Park YM; Jang JW; Lee CK; Sohn JH; Yang JM; Han S
    BMC Gastroenterol; 2013 Apr; 13():74. PubMed ID: 23627926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.
    Illés Á; Pinczés LI; Egyed M
    Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):3-7. PubMed ID: 33118413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.